ArticleBMJ open ophthalmology2026
Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery.
Article in BMJ open ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveElevated intraocular pressure (IOP) is a major risk factor for glaucoma and the primary target of current therapies. When IOP-lowering drugs are insufficient, surgical intervention may be required; however, conjunctival and subconjunctival scarring often limits long-term success. Although intraoperative and postoperative antimetabolite treatments help preserve surgical outcomes, they are associated with ocular side effects. This study investigated the effects of selected anticancer drugs on the proliferation of human Tenon's fibroblasts (HTFs), key mediators of postoperative scarring. METHODS AND ANALYSIS: Primary HTFs were isolated from explants obtained during glaucoma surgery and characterised by immunofluorescence. The cytotoxic effects of candidate drugs were assessed using the MTT and LDH assays, while HTF migration and proliferation were evaluated by wound-healing assays. Additional cytotoxicity testing was performed on primary human trabecular meshwork cells (HTMCs) to assess ocular safety.
resultsUnder the experimental conditions used, HTF proliferation, rather than migration, was the main driver of wound closure. Among the drugs tested, pemigatinib and sorafenib significantly slowed wound closure. Pemigatinib showed no cytotoxicity in either HTFs or HTMCs, whereas sorafenib induced a moderate (28%) cytotoxic effect in HTMCs.
conclusionsPemigatinib and sorafenib, two Food and Drug Administration-approved anticancer agents, effectively reduced HTF proliferation, with pemigatinib showing a more favourable safety profile. These findings identify selective fibroblast growth factor receptor (FGFR) inhibition as a promising strategy for modulating postoperative fibrosis and support further preclinical studies to evaluate the safety and efficacy of FGFR inhibitors as potential adjuncts in glaucoma surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.